Omni Bio Pharm Inc (OMBP) 0.2526 $OMBP
Omni Bio Announces Presentation of Phase 1/2 Clinical Data for AAT at American Heart Association Scientific Sessions
Marketwired - Wed Nov 19, 3:20PM CST
Omni Bio Pharmaceutical, Inc. (PINKSHEETS: OMBP) ("Omni Bio"

, an emerging biopharmaceutical company focused on revolutionizing the treatment of immune-mediated inflammatory diseases, announced today the presentation of Phase 1/2 clinical data for plasma-derived alpha-1 antitrypsin ("p-AAT"

, demonstrating its ability to inhibit the inflammatory response in patients with acute ST-elevation myocardial infarction ("STEMI"

, the most severe type of heart attack. The data were presented yesterday in a poster at the American Heart Association Scientific Sessions 2014, in Chicago. Importantly, these latest clinical findings further highlight the potential value of Omni Bio's first-in-class recombinant AAT candidate, AAT-Fc.
Omni Bio Successfully Completes Cell Line Optimization for Novel Recombinant Biologic
Marketwired - Wed Nov 19, 3:18PM CST
Omni Bio Pharmaceutical, Inc. (OTCBB: OMBP) ("Omni Bio"

, an emerging biopharmaceutical company focused on revolutionizing the treatment of immune-mediated inflammatory diseases, announced today its manufacturing partners, Patheon and Sigma-Aldrich Fine Chemicals (SAFC), have successfully identified several high-expression cell lines able to produce Omni Bio's novel recombinant alpha-1 antitrypsin molecule (AAT-Fc) in large enough quantities to be considered commercially viable. This is a highly significant de-risking milestone that enables Omni Bio to move toward IND-enabling toxicology studies with the first and only pharmaceutically feasible recombinant AAT candidate currently in development.
Omni Bio to Present at 7th Annual BioPharm America Conference
Marketwire - Tue Sep 16, 8:03AM CDT
Omni Bio Pharmaceutical, Inc. (PINKSHEETS: OMBP) ("Omni Bio"

, an emerging biopharmaceutical company focused on revolutionizing the treatment of immune-mediated inflammatory diseases, announced today that it will present at the 7th Annual BioPharm America(TM) 2014 conference, September 22-24, held at the Boston Marriott Copley Place in Boston, MA.
Omni Bio Appoints Jack Riccardi as Chief Financial Officer
Marketwire - Thu Aug 14, 8:03AM CDT
Omni Bio Pharmaceutical, Inc. (PINKSHEETS: OMBP) ("Omni Bio"

, an emerging biopharmaceutical company focused on revolutionizing the treatment of immune-mediated inflammatory diseases, announced today the appointment of Jack Riccardi as its Chief Financial Officer. Mr. Riccardi brings more than 30 years of financial leadership experience. He was formerly CFO of ADial Pharmaceuticals and served most recently as CFO and Partner at Green Street Ventures. Mr. Riccardi's appointment will become effective on September 1, 2014.